it is Noted that on 15 July in accordance with the clinical trial will end up being in the hospital, the first group of volunteers, which tested the safety and tolerability of the new vaccine. “Currently, the health status of all volunteers are good – complaints about the health, adverse reactions or adverse events not observed”, – assured in the military.
After passing the control tests, the volunteers of the first group are discharged from the Main military clinical hospital named after N. Burdenko and return to places of permanent deployment. However, on the 42nd day after the first vaccination volunteers have one day to return to the hospital. As explained by the doctors to undergo final medical examination and diagnosis, as well as preparation of all necessary documents.
the other group of volunteers that conducted study of the efficacy and immunogenicity of a vaccine, Monday, July 13, enter the component number 2 of the drug from the coronavirus. “Booster vaccination scheme provided for the second group of volunteers, allows you to secure immunity and to increase its duration”, – explained in the defense Ministry.
“Received by the specialists of the centre of epidemiology and Microbiology them. Gamalei data indicate the formation of the volunteers the first and second groups of the immune response to the vaccine from COVID-19. Volunteers regularly selected tests for humoral and cellular immunity,” – said military doctors.
Medical specialists of the hospital. Burdenko continue to conduct continuous monitoring of the health status of all volunteers. “There are regular inspections, the selection of physical data of systolic and diastolic blood pressure, pulse rate, body temperature, condition of mucous membranes and skin. Currently, all indicators are normal, common, psychological, and moral status of volunteers – good”, – told in the Ministry of defence.
Recall, may 26, in the meeting via videoconference with Russian President Vladimir Putin, the Russian defense Minister, army General Sergey Shoigu reported that the 48th Central research Institute of NBC protection Ministry of defense in collaboration with the National research centre of epidemiology and Microbiology named after N. F.Gamalei provides the development of recombinant vaccines against novel coronavirus infection. First, on the basis of the 48th Central research Institute of the Ministry of defense was carried out preclinical testing of the vaccine toxicity, safety, immunogenicity, and protective efficacy. Them spent on large and small animals.
on 16 June, the Ministry of health issued a permit to conduct a clinical testtions of the vaccine on volunteers at the Main military clinical hospital named after N. N. Burdenko. The results of the final screening among those on a two-week isolation volunteers was held the final selection of 1st group of participants consisting of 18 people.On 18 June they were vaccinated. Nine volunteers entered one component of the vaccine, nine – two.
among the participants in the experiment includes members of the Armed Forces of the Russian Federation (officers, warrant officers, military men passing military service under the contract in armed forces NBC defence and medical institutions of the Ministry of defense of Russia) and civilian volunteers.
After receiving the results of the survey of the first group of volunteers the primary data on the safety and tolerability of the vaccine, June 23 vaccine was introduced twenty pass screening volunteers.
Volunteers are isolated in a hospital and are under the constant supervision of the most experienced experts of the Main military clinical Burdenko hospital.
Clinical studies of a vaccine against coronavirus is scheduled for completion before the end of July this year.
